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Abstract:  Metabonomics is a well established analytical approach for the analysis of 
physiological regulatory processes via the metabolic profiling of biofluids and tissues in 
living organisms. Its potential is fully exploited in the field of “nutrimetabonomics” that 
aims at assessing the metabolic effects of active ingredients and foods in individuals. Yet, 
one of the greatest challenges in nutrition research is to decipher the critical interactions 
between mammalian organisms and environmental factors, including the gut microbiota. 
“Nutrimetabonomics” is today foreseen as a powerful approach for future nutritional 
programs tailored at health maintenance and disease prevention. 
Keywords:  GC (Gas Chromatography); gut microbiota; MS (Mass Spectrometry); 
metabolomics; metabonomics; metabotypes; NMR (Nuclear Magnetic Resonance) 
Spectroscopy; nutrimetabonomics; personalized nutrition; UPLC (Ultra Performance 
Liquid Chromatography) 
 
 
1. Introduction  
 
Today metabonomics is considered as a well-established system approach to characterize the 
metabolic phenotype of an individual, which results from a coordinated physiological response to 
various intrinsic and extrinsic parameters including environment, drugs, diet, lifestyle, genetics and 
microbiome modulations. Metabonomic analysis refers at the global metabolic profiling of low 
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molecular weight compounds (<1,500 Da) in biofluids (plasma/serum and urine), and tissue extracts or 
biopsies. Such complex biochemical fingerprints of hundreds, or even thousands, of metabolites reflect 
the overall metabolic status of an individual, i.e., its metabonome, as the result of highly complex 
metabolic exchanges within and/or between diverse biological compartments. Since metabolites are 
the end-products of multiple interactions between biological processes, applications of metabonomics 
to nutrition sciences provide an exploratory but unique opportunity to depict the molecular 
mechanisms involved in individual responses to dietary modulations. With the overall aim to provide 
health maintenance, these scientific challenges are today modulated through the understanding of 
metabolic disorders and the efficacy of active ingredients. 
 
2. Metabonomics Analytical Profiling Techniques 
 
The field of metabonomics employs two major analytical techniques based on 
1H-Nuclear Magnetic 
Resonance (NMR) spectroscopy, gas or liquid chromatography coupled to mass spectrometry (GC/MS 
and LC/MS) with lately, the addition of ultrahigh performance liquid chromatography systems coupled 
to mass spectrometers (UPLC/MS) (Figure 1). High-resolution NMR requires little sample 
preparation, offers high sample throughput efficacy (10-15 minutes per sample with a conventional 
detection probe), and high reproducibility. Furthermore, NMR spectroscopy offers the unique 
prospect, other than elucidating the molecular structures, to holistically and simultaneously profile 
metabolites with no a priori selection. The acquired spectral profile reflects the metabolic imprints of 
an individual, which adjust in response to a series of patho-physiological stimuli to maintain 
homeostatic equilibrium. Interestingly, this technique is not only used for the profiling of biological 
fluids (liquid state NMR), but it is also today commonly employed for the study of metabolic profiling 
of intact tissue biopsies, using High Resolution Magic Angle Spinning NMR (HR-MAS). Therefore, 
HR-MAS, presents the unique feature of ensuring the integrity and organizational compartmentation of 
the biological samples. 
However, NMR spectroscopy is inherently less sensitive compared to MS. MS methods are 
commonly employed for global and targeted profiling, and require well adapted sample preparation [1] 
with separation of the metabolites components using either gas chromatography (GC) or liquid 
chromatography (LC) with the more advanced LC (ULPC) being used increasingly. When coupled to 
chromatographic methods, MS can generate comprehensive metabolic profiles of thousands of signals 
within a 15-30 min run time thus enlarging the metabolite window for biomarker identification. 
Multivariate statistical and bioinformatics techniques are ultimately used for data mining the complex 
metabolic profiles which encapsulate information on genetics, environmental factors, gut microbiota 
activity, lifestyle, and food habits. This, at the end, sustains the complex process of identifying 
emerging biomarkers indicative of the individual response to specific physiological factors, and/or 
nutritional interventions and for the elaboration of biological outcomes (Figure 1). 
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Figure 1. Scheme describing a typical NMR (Bruker 600 MHz) and MS (Waters Acquity 
Ultra Performance Liquid Chromatograph) based metabonomic analytical platform. NMR 
offers a holistic profiling of a wide range of metabolites with no a priori selection, while 
MS methods are commonly employed for global and targeted profiling. Both techniques 
are jointly employed. Multivariate statistical techniques are then used for encoding the 
complex metabolic profiles, identification of biomarkers to be ultimately used for the 
elaboration of biological outcome. 
 
 
2.1. Nutritional Metabonomics: Deciphering Food-Induced Metabolic Responses 
 
Metabonomics has shown in the past numerous applications in the study of diseases diagnostics, 
and in the investigation of physiological changes caused by toxic insults [2-12]. Yet, in recent years, 
metabonomics had been also applied in the area of food research. Here the term “nutrimetabonomics” 
entirely describes the mutual link among the fields of metabonomic and nutrition research. Recently, to 
explore how the changes in environmental conditions and lifestyle influence human physiology a 
large-scale metabonomic study was conducted to investigate metabolic phenotype variation across and 
within four human populations groups [13]. The investigations performed on 4630 human subjects 
originating from China, Japan, UK, and USA revealed that the urinary metabolic phenotypes were 
significantly different for East Asian and Western population samples, with contrasting diets, diet-
related major risk factors, and coronary heart disease/stroke rates. Interestingly, it was found that 
urinary excretion of formate is inversely correlated with blood pressure. 
The main goal of nutrimetabonomic studies is therefore to study the effects of selected ingredients 
and foods in healthy individuals [14], specific dietary metabolic imprints in both human basal 
metabolism and gut microbiota metabolic activity had been already shown to be closely related, 
through metabolic profiling of urine, to individual dietary preferences [15]. Additionally, 
nutrimetabonomics was also used to study the health benefits of caloric restriction (CR) dieting in Nutrients 2009, 1                                       
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nonhuman primates [16]. Here, for instance, the authors showed, by applying holistic NMR profiling 
of blood plasma, marked evidence of reduced aging-depended alteration of energy and lipoprotein 
metabolism, thus revealing key mechanistic regulatory long terms effects of CR.  
Other works demonstrated the potential of metabolic profiling for surveying the outcome of 
nutritional interventions for modulating and preventing metabolic deregulations [17,18]. Recently, 
metabonomics has been applied in combination with measures of blood plasma inflammatory 
biomarkers and histopathology of gut tissues to elucidate the mechanistic basis and biochemical events 
behind inflammatory bowel disease (IBD) [19]. By following the gradual development of colitis in a 
Interleukin 10 knock out mouse model, with selected spontaneous chronic inflammation, holistic 
metabolic profiling of blood plasma revealed a gradual disruption of energy homeostasis, profound 
impairment of lipoprotein, phospholipids and polyunsaturated fatty acids metabolism, and an altered 
glycosylated protein profile. In addition, IL 10 knock out mice displayed higher levels of lactate, 
pyruvate, citrate, and higher concentration of free amino acids. All together these metabolic changes 
indicate increased fatty acid oxidation and glycolysis, with higher levels of circulating amino acids 
reflecting muscle atrophy, increase breakdown of proteins and energy production by interconversion of 
amino acids.  
Much attention today is also given to the use of probiotic supplements as a means to promote gut 
health preventing allergies and inflammatory incidences. The effects of a therapeutic intervention with 
probiotics on normalizing the metabolic disorders acquired in post-infective irritable bowel syndrome 
were monitored using both systemic and tissue-specific metabolic profiling [20]. These investigations 
highlighted metabolic discrepancies in relation with muscular hyper-contractility and hypertrophy, and 
gut microbial disturbance, which were modulated by the probiotic intervention.  
Yet, while many applications in the very next future can be easily envisioned, with personalized 
nutrition programs as the main objective, nutrimetabonomics remains today an extremely complex 
science to decipher. Indeed, food-induced metabolic changes are not only the end results of many 
complex interactions among many active molecules, but also vary extremely among individuals as 
differences in endogenous factors such as age, environment, genetics, lifestyle, and gut microbiota 
strongly influence individual responses. For this reason, to maximize the control over these variables 
and to exclude fictitious interpretations, when analyzing the effects of specific nutritional intervention 
programs, it is imperative to employ appropriate experimental designs. This is limited most of the time 
to rigorous inclusion/exclusion criteria and accurate collection of individual dietary and feeding habits. 
 
2.2. Nutrimetabonomics: A Specific Tool to Decipher Gut Microbiota Contribution to the Host 
Metabolic Homeostasis Processes 
 
The contribution of the gut microbiota on the mammalian metabolism had been recently deeply 
investigated [21-25]. Adult humans carry thousands of gut microbial symbiotic organisms that are in 
close correlation with the metabolism and immune systems of the hosts [26]. It is now evident that, not 
only there is a strong relationship among humans and their gut bacteria, but it is now apparent that the 
gut microbiota exerts a deep control over multiple host cell metabolic pathways [27-29]. Recent 
findings highlighted the gut microbiota as a key determinant in the etiology of many disease, including 
insulin resistance [30], obesity [31,32], food allergies [33], gastritis and peptide ulcers [34,35] Nutrients 2009, 1                                       
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cardiovascular diseases [36], Crohn’s disease [37], irritable bowel syndrome [38], and gastro-intestinal 
cancers [21]. Undeniably, today the gut microbiota can be considered as an extra-genomic functional 
unit that imparts mechanistic control, determining the metabotypes, over the host nutritional health 
(Figure 2). Besides, there is today a strong need to successfully apply personalized healthcare solutions 
in deciphering the role of these interactions.  
Indeed, the symbiotic relationships among animals and their gut had been extensively studied by 
Martin et al. who describe at first a top-down view model of the effects of different gut microbiome on 
murine metabolic profiles [39]. The authors reported that inoculation of germ-free mice with a 
simplified model of human baby microbiota modifies the physiology of the murine host towards pre-
pathological conditions. The metabonomic investigations brought evidence of a functional relationship 
between the modulation of the bile acid pool, impaired lipid metabolism and gut microbial 
composition. In particular, the human-derived bacteria were non-adapted to the murine organism and 
unable to hydrolyze tauro-conjugated bile acids. These metabolic alterations resulted in decreased 
capability of dietary lipid emulsification and higher intestinal lipid absorption, which in turn altered 
the proper recirculation and distribution of fat within the organism. 
The breadth and the depth of gut microbiome modulations of host biochemistry in this mouse model 
were further explored by modulating the gut functional ecology with pro-, pre-, and synbiotics [40-42]. 
Gut microbes perform multiple digestive and metabolic functions for the host and these studies 
revealed that major mammalian metabolic processes are under symbiotic homeostatic control. For 
instance, the effects of consuming live microbial supplements, probiotics, on the microbial ecology 
host health and nutritional status have been in the past years investigated [43]. These factors were well 
elucidated by measuring the transgenomic metabolic effects of exposure to Lactobacillus paracasei 
and Lactobacillus rhamnosus probiotics in mice inoculated with a simplified model of human gut 
microbiota. Changes in dietary carbohydrate and protein processing by gut bacteria with subsequent 
influence on host lipids and energy metabolism were revealed by the analysis of systemic fluids, liver, 
stools, and intestinal contents. 
As an alternative, the combined use of prebiotics and probiotics may offer superior effects in health 
maintenance through modulating the microbial functional ecology [42]. Here, metabonomics was able 
to captured metabolic changes in selected biological compartments, biofluids and liver, which were 
correlated with modulation in microbial populations. In turn, these microbial effects were associated 
with changes in various host metabolic pathways including gluconeogenesis, amino acids, 
methylamine and lipid metabolism.  
Additionally, in a follow up paper, the authors analyzed the effects of single prebiotics and 
probiotics and their synbiotic effects on the metabolic status of germfree mice during the establishment 
of a simplified model of human microbiota. In this paper, to properly assess the dietary modulations of 
the gut microbota at a system level, multicompartmental modeling approach with metabolic imprints 
from 10 tissue/fluid samples was applied [40]. Interestingly, the authors revealed that the induced 
microbial changes influenced host lipid, carbohydrate, and amino acid metabolism in every major 
mammalian biological analyzed compartment. Specifically, it was found that galactosyl-
oligosaccharides strongly reduced lipogenesis, triacylglycerol incorporation into lipoproteins and 
triglyceride concentration in the liver and the kidney. Prebiotic modulation of the gut microbiota also 
altered transmethylation metabolic pathways in the liver and in the pancreas, with inferred effects on Nutrients 2009, 1                                       
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the control of glucose metabolism and insulin sensitivity. In addition, to the previously characterized 
metabolic effect of probiotics in reducing hepatic glycogen and glutamine levels, these studies brought 
compelling evidence of decreased adrenal ascorbate levels, with plausible implications in energy 
homeostasis, antioxidation, and steroidogenesis.  
While deciphering the interactions between the gut microbiota and the host remains a very 
challenging process, research advances in recent years have positively elucidated key metabolic 
processes disclosing in depth how the gut microbiota exert control over the host’s biochemistry. 
Imperative for the development of nutritional management programs and for the amelioration of 
individual health will be in the very next future to comprehensively embrace the full dynamics of these 
interactions. 
 
Figure 2. Scheme describing the symbiotic relationship among the host and their gut 
bacteria, with the gut microbiota exerting a deep control over multiple host cell metabolic 
regulatory functions. 
 
 
3. Conclusions 
 
As previously expressed one of the greatest challenges in modern nutrition research is to decipher 
how changes in the environment and lifestyle conditions regulate not only human physiology but 
additionally human ability to attain different nutritional needs. With these aims, the analysis of 
biofluids by metabonomic means permits the assessment of spatiotemporal interorgan metabolic cross-
talk, while the analysis of such information by complex data mining techniques allow the assessment 
of the functional relationships among different biological compartments. Specifically, the combination 
of metabolic profiling and multivariate analysis was successfully proved to infer inter-compartment 
metabolite relationships from plasma, liver, pancreas, adrenal gland and kidney cortex samples [44]. 
Such a combination of chemometric techniques could provide new research avenues to assess the 
efficacy of nutritional interventions on targeted organs from the single analysis of a systemic fluid 
such as the plasma. 
Modern nutritional research focuses on health promotion and disease prevention through diets. 
Nutritional solutions have indeed been developed for the management of several chronic conditions, 
such as obesity and type 2 diabetes. It is therefore expected that, for this scope, nutrition and health Nutrients 2009, 1                                       
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will commonly aim in the very next future into the optimization of food products specifically tailored 
to match consumer specific needs to promote health and wellness. Metabonomics will provide the 
required instruments to monitor the metabolic health of consumers and maintaining homeostatic 
balance. Indeed, adjusting the diet according to the health status will be one of the projected benefits.  
The change of adapting personalized nutritional programs will not only lie in the diagnostic tools, 
consumer demands and awareness, or measuring technology, but will mostly rely on sound scientific 
bases. Such processes had been already proven to be well initiated. 
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